European Medicines Agency Recommends Refusal of the Marketing Authorisation for Masitinib


On 21 November 2013, the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product masitinib (Masican), intended for the treatment of malignant gastrointestinal stromal tumour (GIST).

No relation
26/11/2013 11:04 am
There are no related objects.